Nuveen’s LB Pharmaceuticals LBRX Stock Holding History

Nuveen’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69M	Buy	52,142 +29,176	+127%	+$857K	﹤0.01%	2661
2026 Q1	$566K	Hold	22,966	–	–	﹤0.01%	2790
2025 Q4	$511K	Buy	+22,966	New	+$401K	﹤0.01%	2861

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Nuveen's LBRX Position: Q2 2026 in Review

Nuveen increased its LB Pharmaceuticals (LBRX) stake by 127% in Q2 2026, buying an estimated $857K and bringing the position to 52,142 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Nuveen first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

Nuveen held 52,142 shares of LB Pharmaceuticals worth $1.69M as of Q2 2026.
Nuveen bought 29,176 LB Pharmaceuticals shares in Q2 2026, an estimated $857K.
LB Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2661 holding.
Nuveen first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.